Xcout Intel
Neumirna
Neumirna Therapeutics is a biotechnology company founded in 2021 and headquartered in Copenhagen, Denmark. The firm is dedicated to pioneering RNA-based therapies to treat epilepsy, Parkinson's disease, and other neurological disorders.
Subscribe to see Neumirna’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Neumirna at a glance
Neumirna is a biotech company headquartered in Denmark. Its most recent funding round, Series A, raised $21.6M in January 2025. Xcout tracks 12 named people at Neumirna, including Ellen Donnelly, PhD (CEO).
Neumirna leadership
- Ellen Donnelly, PhDCEO
- Janine ErlerCEO
- Peter RasmussenCFO
- Ferenc TracikCMO
- Ina Brünig-Traebert, PhDCDO
- Henrik KlitgaardScientific Co-Founder
6 more named people on record for Neumirna, with roles, board committees and tenure — see the full roster →
Neumirna funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $21.6M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Neumirna competitors
A few of Neumirna's closest competitors — see the full list of competitors and alternatives →
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Harness Therapeutics Ltd. is a biotechnology company founded in 2023 and based in Cambridge, United Kingdom. The company focuses on RNA biology and the development of novel therapeutics for the treatment of neurodegenerative diseases.
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Neurona Therapeutics Inc. is a biotherapeutics company that focuses on developing cell-based therapies to address neurological disorders.
Neuron23 is a biotechnology company founded in 2018 that focuses on developing precision therapeutics for genetic diseases. Headquartered in South San Francisco, California, the company relies on a team of scientific experts and entrepreneurs.
Umecrine Cognition AB is a Swedish clinical-stage pharmaceutical company based at the Karolinska Institutet Science Park in Solna, developing a novel class of drugs to treat neurological disorders of the brain.
Get Neumirna's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Neumirna in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access